Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority.
If you are confused about the plethora of lipid-lowering agents now available and have not been able to read all the latest studies, you are not alone. It is almost impossible for busy physicians to keep up with this rapidly growing area of research. Drs Bays and Dujovne provide an update of the major antihyperlipidemics, along with a discussion of how to select patients for this therapy and the relative cost-effectiveness of the different types of therapy.
Bays
H E
HE
Lipid Center, Humana Heart Institute International, Louisville, KY 40217.
Dujovne
C A
CA
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D004347:Drug Interactions; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D008055:Lipids / Q000097:blood; D012307:Risk Factors
D000960:Hypolipidemic Agents; D008055:Lipids